A U.S. Food and Drug Administration (FDA) advisory committee recently determined that phenylephrine, an ingredient commonly used to treat sinus and nasal congestion, is ineffective in treating these symptoms. This was apparent from research for years, yet large...
News
Latest News
Rubio Habla en La Poderosa
El senador estadounidense Marco Rubio (R-FL) habló con César Grajales de La Poderosa 670 AM en El Panorama Político, sobre la crisis fronteriza, sobre cómo los hispanoamericanos se ven afectados con la realidad del país, sobre los cargos contra el senador Bob Menéndez...
Rubio, Colleagues Reintroduce Bill to Protect Rights of Pregnant Students
Pregnant students are sometimes discriminated against by their schools, either intentionally or unintentionally and there is a concerning lack of awareness about the resources and rights available to them. Due to a lack of services and discrimination, these women may...
Rubio, Colleagues Reintroduce Intelligence Community Workforce Agility Protection Act
Currently, intelligence community civilians are subject to certain tax penalties for job-related relocation requirements, but active-duty military servicemembers are not subjected to the same penalties. These tax benefits, including the ability to deduct moving...
Rubio Delivers Remarks at Senate Intelligence Hearing
Vice Chairman of the Senate Select Committee on Intelligence Marco Rubio (R-FL) delivered opening remarks and questioned witnesses at a hearing on countering China’s influence in the United States. Watch Rubio’s opening remarks here as well as Part I and Part II of...
Rubio-led Resolution to Raise Awareness for Spinal Cord Injuries Passes Senate
Approximately 302,000 Americans live with spinal cord injuries. To help these people achieve a better quality of life, there is a need to increase education and invest in research. U.S. Senators Marco Rubio (R-FL) and Tammy Baldwin (D-WI) successfully led a bipartisan...
Rubio, Coons Reintroduce Bipartisan Legislation to Improve Small Business Ability to Commercialize
Washington, D.C. — U.S. Senators Marco Rubio (R-FL) and Chris Coons (D-DE) reintroduced the Research Advancing to Market Production (RAMP) for Innovators Act, which would improve small businesses’ ability to commercialize in the U.S. Small Business Administration’s (SBA) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. The RAMP for Innovators Act, which Rubio and Coons first introduced in July 2019, would expand access to research and development awards with preference to small firms with high growth potential, improve technical and business assistance, assess small business commercialization impact, and assist firms with the intellectual property protection process. U.S. Representatives Chrissy Houlahan (D-PA) and Troy Balderson (R-OH) introduced companion legislation in the U.S. House of Representatives.
“The pandemic highlighted America’s supply chain vulnerabilities and our overreliance on countries like China,” Rubio said. “It is more important than ever that we harness the strength and ingenuity of small businesses across the country to scale up our domestic manufacturing and innovation. This legislation would help startups and other small business innovators access federal research and development dollars, protect their intellectual property, and commercialize.”
“Small businesses are America’s engine of innovation, and with support in bringing their ideas to market, these startups can drive job growth and strengthen our economic security,” Coons said. “Helping startups access financial support and business advice means that they can focus on turning promising technology into innovative products that increase the prosperity and security of our nation. I’m proud to partner again with Senator Rubio to help innovative small manufacturers bring their technologies to the market.”
Specifically, the Research Advancing to Market Production (RAMP) for Innovators Act would:
- Improves the timeliness of SBIR/STTR decision proposals, prioritizes firms with a likelihood of commercialization, and expands Direct to Phase II flexibility;
- Requires the SBA to coordinate all agencies to develop a commercialization impact assessment;
- Directs the SBA Administrator to coordinate with the United States Patent and Trade Office to allow some SBIR recipients priority and fee waivers with the OneTrack patent program, and
- Creates a designated technology commercialization official at each participating agency to provide assistance to awardees in commercializing and transitioning technologies, and report to the SBA actions taken to simplify, standardize, and expedite the process.